CN Patent

CN120309684A — 靶向化合物及其用途

Assigned to Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co · Expires 2025-07-15 · 1y expired

What this patent protects

本发明提供了可以特异性结合至整联蛋白αvβ6的靶向化合物，所述化合物为本发明所述式I所示化合物。所述靶向化合物可用于转运递送活性分子至表达整联蛋白αvβ6的细胞或组织。

USPTO Abstract

本发明提供了可以特异性结合至整联蛋白αvβ6的靶向化合物，所述化合物为本发明所述式I所示化合物。所述靶向化合物可用于转运递送活性分子至表达整联蛋白αvβ6的细胞或组织。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN120309684A
Jurisdiction: CN
Classification: —
Expires: 2025-07-15
Drug substance claim: No
Drug product claim: No
Assignee: Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.